So long Exubera
This morning Pfizer (NYSE:PFE) stated, “Meanwhile, we made an important decision regarding Exubera, a product for which we initially had high expectations,” said Jeff Kindler, Chairman and Chief Executive Officer. “Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted.”
“We will work with physicians to transition Exubera patients to other treatment options in the next three months. We remain committed to investing significant resources in the development of new and innovative medicines to manage diabetes, including monitoring inhalation technologies and other innovative delivery systems for insulin and other medicines.”
Exubera, a product Diabetic Investor said would never reach the lofty sales estimates made by Pfizer and many analysts is now history. Perhaps with Exubera’s demise people will wake up and start realizing that there is more to insulin therapy than how the insulin is delivered. Pfizer wasted billions trying to convince people that patients would use Exubera just because they did not have to inject insulin.
While many will see this as end of inhaled delivery of insulin, Diabetic Investor doesn’t see it that way. Exubera did not fail because the insulin was inhaled. Exubera failed for a number of reason which Diabetic Investor has outlined on numerous occasions. With the epidemic growth rate of diabetes and the increasing usage of insulin with type 2 patients, there is a market for an inhaled form of insulin. Hopefully the companies that have inhaled systems under development will learn from Pfizer’s many mistakes with Exubera.
Told you so!!!!!
David Kliff
Publisher
Diabetic Investor
www.diabeticinvestor.com
www.davesrunfordiabetes.blogspot.com
847-634-4777
800-783-3712
847-634-4646 fax
224-715-3761 mobile
